Catheter Precision Announces New FDA 510(k) Clearance for its VIVO System, Enabling Use in a Broader Patient Population

What happened

Catheter Precision, a wholly owned subsidiary of Flyte Aviation, announced that the FDA cleared expanded labeling for its VIVO system. The clearance allows its use in a broader group: patients with structural heart disease undergoing catheter ablation for monomorphic ventricular tachycardia.

Confirmed

Global impact / market context

The clearance expands the patient group for which VIVO can be used, potentially giving physicians another tool in complex heart procedures. If hospitals adopt it, use could support revenue for Catheter Precision; the article provides no sales forecasts or evidence of adoption.

Analyst inference

The article describes catheter ablation as underused for ventricular tachycardia, citing lengthy procedures and inconsistent outcomes, while standard care relies heavily on implanted defibrillators and medicines. The new clearance broadens VIVO’s permitted use, but does not establish clinical superiority or commercial demand.

Confirmed

What to watch

1. Look for evidence that hospitals and physicians begin using VIVO for the newly cleared patients; adoption would be the step connecting regulatory clearance to potential sales. Analyst inference
2. Watch for further company details on clinical results in patients with structural heart disease, including whether the reported accuracy and safety claims are supported with specific data. Analyst inference
3. The FDA clearance covers patients with structural heart disease undergoing catheter ablation for monomorphic ventricular tachycardia; the article gives no adoption, revenue, or timing figures. Confirmed

Evidence

• globenewswire.com